These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 17323649)

  • 1. Bactericidal efficacy of ABI-0043, a novel rifamycin, in a murine pneumococcal pneumonia model.
    Lee SY; Tessier PR; Murphy CK; Nicolau DP
    J Antibiot (Tokyo); 2006 Dec; 59(12):804-7. PubMed ID: 17323649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of pulsatile amoxicillin and clarithromycin dosing alone and in combination in a murine pneumococcal pneumonia model.
    Sun HK; Lee SY; Banevicius MA; Du X; Maglio D; Nicolau DP
    J Antimicrob Chemother; 2005 Sep; 56(3):559-65. PubMed ID: 16024590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro pharmacodynamics of novel rifamycin ABI-0043 against Staphylococcus aureus.
    Tsuji BT; Yang JC; Forrest A; Kelchlin PA; Smith PF
    J Antimicrob Chemother; 2008 Jul; 62(1):156-60. PubMed ID: 18400804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumor necrosis factor antibody impairs the therapeutic effect of ceftriaxone in murine pneumococcal pneumonia.
    Rijneveld AW; Florquin S; Hartung T; Speelman P; van der Poll T
    J Infect Dis; 2003 Jul; 188(2):282-5. PubMed ID: 12854084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose aerosol model of pneumococcal pneumonia in the mouse: utility for evaluation of antimicrobial efficacy.
    Nuermberger E; Helke K; Bishai WR
    Int J Antimicrob Agents; 2005 Dec; 26(6):497-503. PubMed ID: 16289711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of fosfomycin alone and in combination with ceftriaxone or vancomycin in an experimental model of meningitis caused by two strains of cephalosporin-resistant Streptococcus pneumoniae.
    Ribes S; Taberner F; Domenech A; Cabellos C; Tubau F; Liñares J; Viladrich PF; Gudiol F
    J Antimicrob Chemother; 2006 May; 57(5):931-6. PubMed ID: 16507562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Murine models of pneumococcal pneumonia and their applicability to the study of tissue-directed antimicrobials.
    Nuermberger E
    Pharmacotherapy; 2005 Dec; 25(12 Pt 2):134S-139S. PubMed ID: 16305283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rifampicin+ceftriaxone versus vancomycin+ceftriaxone in the treatment of penicillin- and cephalosporin-resistant pneumococcal meningitis in an experimental rabbit model.
    Suntur BM; Yurtseven T; Sipahi OR; Buke C; Buke M
    Int J Antimicrob Agents; 2005 Sep; 26(3):258-60. PubMed ID: 16099624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ceftriaxone pharmacokinetics in interleukin-10-treated murine pneumococcal pneumonia.
    Wang E; Bergeron Y; Bergeron MG
    J Antimicrob Chemother; 2005 May; 55(5):721-6. PubMed ID: 15772139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo activity and pharmacokinetics of ziracin (SCH27899), a new long-acting everninomicin antibiotic, in a murine model of penicillin-susceptible or penicillin-resistant pneumococcal pneumonia.
    Wang E; Simard M; Bergeron Y; Beauchamp D; Bergeron MG
    Antimicrob Agents Chemother; 2000 Apr; 44(4):1010-8. PubMed ID: 10722505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Streptococcus pneumoniae: does antimicrobial resistance matter?
    Lynch JP; Zhanel GG
    Semin Respir Crit Care Med; 2009 Apr; 30(2):210-38. PubMed ID: 19296420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of specific neutrophil elastase inhibitor, sivelestat sodium hydrate, in murine model of severe pneumococcal pneumonia.
    Yanagihara K; Fukuda Y; Seki M; Izumikawa K; Miyazaki Y; Hirakata Y; Tsukamoto K; Yamada Y; Kamhira S; Kohno S
    Exp Lung Res; 2007 Mar; 33(2):71-80. PubMed ID: 17454103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial-resistant Streptococcus pneumoniae: trends and management.
    Jacobs MR
    Expert Rev Anti Infect Ther; 2008 Oct; 6(5):619-35. PubMed ID: 18847402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic recombinant murine activated protein C attenuates pulmonary coagulopathy and improves survival in murine pneumococcal pneumonia.
    Schouten M; van 't Veer C; van den Boogaard FE; Gerlitz B; Grinnell BW; Roelofs JJ; Levi M; van der Poll T
    J Infect Dis; 2010 Nov; 202(10):1600-7. PubMed ID: 20925531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic use of the endolysin Cpl-1 rescues mice with fatal pneumococcal pneumonia.
    Witzenrath M; Schmeck B; Doehn JM; Tschernig T; Zahlten J; Loeffler JM; Zemlin M; Müller H; Gutbier B; Schütte H; Hippenstiel S; Fischetti VA; Suttorp N; Rosseau S
    Crit Care Med; 2009 Feb; 37(2):642-9. PubMed ID: 19114881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increasing ceftriaxone resistance and multiple alterations of penicillin-binding proteins among penicillin-resistant Streptococcus pneumoniae isolates in Taiwan.
    Chiu CH; Su LH; Huang YC; Lai JC; Chen HL; Wu TL; Lin TY
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3404-6. PubMed ID: 17591850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of cefditoren and other antimicrobial agents against 288 Streptococcus pneumoniae and 220 Haemophilus influenzae clinical strains isolated in Zaragoza, Spain.
    Seral C; Suárez L; Rubio-Calvo C; Gómez-Lus R; Gimeno M; Coronel P; Durán E; Becerril R; Oca M; Castillo FJ
    Diagn Microbiol Infect Dis; 2008 Oct; 62(2):210-5. PubMed ID: 18715733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of amoxycillin-clavulanate in an experimental model of murine pneumonia caused by AmpC-non-hyperproducing clinical isolates of Escherichia coli resistant to cefoxitin.
    Docobo-Pérez F; Fernández-Cuenca F; Pachón-Ibáñez ME; Pascual A; Pichardo C; Martínez-Martínez L; Pachón J
    Clin Microbiol Infect; 2008 Jun; 14(6):582-7. PubMed ID: 18294246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel substituted (pyridin-3-yl)phenyloxazolidinones: antibacterial agents with reduced activity against monoamine oxidase A and increased solubility.
    Reck F; Zhou F; Eyermann CJ; Kern G; Carcanague D; Ioannidis G; Illingworth R; Poon G; Gravestock MB
    J Med Chem; 2007 Oct; 50(20):4868-81. PubMed ID: 17722903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Penicillin-resistant pneumococcus and risk of treatment failure in pneumonia.
    Cardoso MR; Nascimento-Carvalho CM; Ferrero F; Berezin EN; Ruvinsky R; Camargos PA; Sant'anna CC; Brandileone MC; de Fátima P March M; Feris-Iglesias J; Maggi RS; Benguigui Y;
    Arch Dis Child; 2008 Mar; 93(3):221-5. PubMed ID: 17848490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.